TopMarketGainers
Long

$GNCA UP PREMARKET ON POSITIVE CANCER VACCINE DATA

NASDAQ:GNCA   GENOCEA BIOSCIENCES INC
****COULD BE A GREAT MOVE IN THE DAYS TO SOME, AFTER VERY POSITIVE DATA FOR THEIR GEN-009 CANCER VACCINE******
Joseph Pantginis also upgraded the stock to $42 today, he states,
“Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our price target to $42 from $5.75. The factors impacting our target change include: (1) adjustment to base year; and (2) adjustment to fully diluted share count subsequent to the 8 reverse split.”



COMPANY PROFILE
Genocea Biosciences , Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine.
Do you want to GAIN an Edge on Wall Street?

1) Sign Up for our Free Email Newsletter @
http://www.TopMarketGainers.com

2) Receive Free Text Message (SMS) Notifications
by Texting 'GAINS' to 67076.

(*It's FREE, however Msg&Data rates may apply.)
Home Stock Screener Forex Screener Crypto Screener Economic Calendar Shows How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Refer a friend My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out